Seebri Breezhaler Use In Pregnancy & Lactation

Pregnancy: There are no data from the use of Seebri Breezhaler in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.
Breast-feeding: It is unknown whether glycopyrronium bromide is excreted in human milk. However, glycopyrronium bromide (including its metabolites) was excreted in the milk of lactating rats (see Pharmacology: Toxicology: Preclinical safety data under Actions). The use of glycopyrronium by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Fertility: Reproduction studies and other data in animals do not indicate a concern regarding fertility in either males or females (see Pharmacology: Toxicology: Preclinical safety data under Actions).